company background image
RMDA logo

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) CASE:RMDA Stock Report

Last Price

ج.م4.73

Market Cap

ج.م7.1b

7D

8.5%

1Y

129.6%

Updated

30 Apr, 2025

Data

Company Financials +

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E)

CASE:RMDA Stock Report

Market Cap: ج.م7.1b

RMDA Stock Overview

Produces and sells a range of branded generic pharmaceuticals, food supplements, veterinary products, and nutraceuticals in Egypt. More details

RMDA fundamental analysis
Snowflake Score
Valuation1/6
Future Growth5/6
Past Performance3/6
Financial Health2/6
Dividends1/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) Competitors

Price History & Performance

Summary of share price highs, lows and changes for Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E)
Historical stock prices
Current Share Priceج.م4.73
52 Week Highج.م4.79
52 Week Lowج.م1.85
Beta0.23
1 Month Change7.50%
3 Month Change31.39%
1 Year Change129.61%
3 Year Change222.94%
5 Year Change128.53%
Change since IPO111.03%

Recent News & Updates

Recent updates

Shareholder Returns

RMDAEG PharmaceuticalsEG Market
7D8.5%4.9%3.5%
1Y129.6%46.4%35.3%

Return vs Industry: RMDA exceeded the EG Pharmaceuticals industry which returned 46.4% over the past year.

Return vs Market: RMDA exceeded the EG Market which returned 35.3% over the past year.

Price Volatility

Is RMDA's price volatile compared to industry and market?
RMDA volatility
RMDA Average Weekly Movement6.4%
Pharmaceuticals Industry Average Movement5.2%
Market Average Movement4.7%
10% most volatile stocks in EG Market8.4%
10% least volatile stocks in EG Market3.0%

Stable Share Price: RMDA's share price has been volatile over the past 3 months compared to the EG market.

Volatility Over Time: RMDA's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of EG stocks.

About the Company

FoundedEmployeesCEOWebsite
1986n/aAmr Morsywww.ramedapharma.com

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E), together with its subsidiaries, produces and sells a range of branded generic pharmaceuticals, food supplements, veterinary products, and nutraceuticals in Egypt. The company manufactures, markets, sells, and stores pharmaceutical reagents for human and veterinary use, and diagnostic reagents for individuals, laboratories, and hospitals; imports pharmaceutical reagents and raw materials; and produces food supplements for human use. It offers a portfolio of products in various therapeutic areas, such as anti-biotics, cardiovascular diseases and gastro-intestinal tract disorders, anti-infectives, alimentary tract and metabolism, genito-urinary system, nervous system, blood forming organs, weight management, and sex hormones.

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) Fundamentals Summary

How do Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E)'s earnings and revenue compare to its market cap?
RMDA fundamental statistics
Market capج.م7.11b
Earnings (TTM)ج.م363.84m
Revenue (TTM)ج.م2.77b

19.5x

P/E Ratio

2.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RMDA income statement (TTM)
Revenueج.م2.77b
Cost of Revenueج.م1.49b
Gross Profitج.م1.28b
Other Expensesج.م917.63m
Earningsج.م363.84m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.24
Gross Margin46.28%
Net Profit Margin13.14%
Debt/Equity Ratio75.0%

How did RMDA perform over the long term?

See historical performance and comparison

Dividends

1.4%

Current Dividend Yield

38%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/30 22:41
End of Day Share Price 2025/04/30 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Eman MareeArab African International Securities
Ahmed RashadBeltone Financial
Marina MikhailCI Capital Research